Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Johannes Schmoellerl, Romana Maerschalk, Martina Weissenboeck, Jasmin Ali, Thomas Köcher, Aleksandra Bundalo, Florian Andersch, Vivien Vogt, Bettina Sajtos, Jonas Bayerl, Martina Minnich, Michaela Fellner, Johannes Zuber

Blood (2024) 144 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2024-211758

Published: 2024

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

SBNO2 is a critical mediator of STAT3-driven hematological malignancies

Tania Brandstoetter, Johannes Schmoellerl, Reinhard Grausenburger, Sebastian Kollmann, Eszter Doma, Jani Huuhtanen, Thorsten Klampfl, Thomas Eder, Florian Grebien, Gregor Hoermann, Johannes Zuber, Satu Mustjoki, Barbara Maurer, Veronika Sexl

Blood (2023) 141 (15): 1831–1845.

https://doi.org/10.1182/blood.2022018494

Published: 2023

Includes: Supplemental data

Journal Articles

EVI1 drives leukemogenesis through aberrant ERG activation

Johannes Schmoellerl, Inês A.M. Barbosa, Martina Minnich, Florian Andersch, Leonie Smeenk, Marije Havermans, Thomas Eder, Tobias Neumann, Julian Jude, Michaela Fellner, Anja Ebert, Monika Steininger, Ruud Delwel, Florian Grebien, Johannes Zuber

Blood (2023) 141 (5): 453–466.

https://doi.org/10.1182/blood.2022016592

Published: 2023

Includes: Supplemental data

Journal Articles

Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Dorien Pastoors, Marije Havermans, Remco Hoogenboezem, Roger Mulet-Lazaro, Duncan Brian, Leonie Smeenk, Claudia Erpelinck-Verschueren, Stanley van Herk, Bas Wouters, Jeroen A.A. Demmers, Johannes Zuber, Tariq Enver, Richard WJ Groen, Eric Bindels, Ruud Delwel

Blood (2022) 140 (Supplement 1): 83–84.

https://doi.org/10.1182/blood-2022-156994

Published: 2022

Journal Articles

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140776

Published: 2020

Journal Articles

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

Blood (2020) 136 (8): 957–973.

https://doi.org/10.1182/blood.2019002548

Published: 2020

Includes: Supplemental data

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Blood (2019) 134 (Supplement_1): 109.

https://doi.org/10.1182/blood-2019-122483

Published: 2019

Journal Articles

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

Barbara Peter, Gregor Eisenwort, Alexandra Keller, Karin Bauer, Daniela Berger, Irina Sadovnik, Gabriele Stefanzl, Gregor Hoermann, Dominik Wolf, Zdenek Racil, Jiří Mayer, Johannes Zuber, Wolfgang R. Sperr, Georg E. Winter, Michael Willmann, Thomas Rülicke, Peter Valent

Blood (2018) 132 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2018-99-111126

Published: 2018

Journal Articles

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Blood (2018) 132 (18): 1936–1950.

https://doi.org/10.1182/blood-2018-02-833582

Published: 2018

Includes: Supplemental data

Journal Articles

RNAi and CRISPR/Cas9 Based In Vivo Models for Drug Discovery

Prem Premsrirut, MD PhD, Chia-Lin Wang, PhD, Yu-ting Yang, PhD, Christof Fellmann, PhD, Lukas Dow, PhD, Johannes Zuber, PhD, Scott Lowe, PhD, Marina Pesic, PhD, Katharina Wolter, PhD, Lars Zender, PhD

Blood (2017) 130 (Supplement 1): 5568.

https://doi.org/10.1182/blood.V130.Suppl_1.5568.5568

Published: 2017

Journal Articles

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Blood (2017) 129 (21): 2882–2895.

https://doi.org/10.1182/blood-2016-05-718171

Published: 2017

Includes: Supplemental data

Journal Articles

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Georg Greiner, Nadine Witzeneder, Angelika Berger, Klaus Schmetterer, Gregor Eisenwort, Ana-Iris Schiefer, Simone Roos, Theresia Popow-Kraupp, Leonhard Müllauer, Johannes Zuber, Veronika Sexl, Lukas Kenner, Wolfgang R. Sperr, Peter Valent, Matthias Mayerhofer, Gregor Hoermann

Blood (2017) 129 (3): 371–382.

https://doi.org/10.1182/blood-2016-09-739003

Published: 2017

Includes: Supplemental data

Journal Articles

Uncovering Key Downstream Effectors of PU.1 Tumor Suppression in Acute Myeloid Leukemia

Margherita Ghisi, PhD, Mark D McKenzie, PhD, Ethan P Oxley, Emilia Simankowicz, Cynthia Liu, Aleksandar Dakic, PhD, Stephen L Nutt, PhD, Matthew E Ritchie, PhD, Johannes Zuber, MD PhD, Ross A Dickins, PhD

Blood (2016) 128 (22): 2698.

https://doi.org/10.1182/blood.V128.22.2698.2698

Published: 2016

Journal Articles

The Transcription Factor PU.1 Controls a Reversible Differentiation Program in Acute Myeloid Leukemia

Mark D McKenzie, PhD, Margherita Ghisi, PhD, Luisa Cimmino, PhD, Michael Erlichster, Ethan P Oxley, Cynthia Liu, Matthew T Witkowski, PhD, Grace Liu, PhD, Aleksandar Dakic, PhD, Emilia Simankowicz, Ladina DiRago, Donald Metcalf, MD, Stephen L Nutt, PhD, Meaghan Wall, MBBS, PhD FRACP, FRCPA, Matthew E Ritchie, PhD, Johannes Zuber, MD PhD, Ross A Dickins, PhD

Blood (2016) 128 (22): 3930.

https://doi.org/10.1182/blood.V128.22.3930.3930

Published: 2016

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Barbara Peter, DVM, Gregor Eisenwort, Gabriele Stefanzl, Daniela Berger, Wolfgang R Sperr, MD, Johannes Zuber, MD PhD, Peter Valent, MD

Blood (2015) 126 (23): 1571.

https://doi.org/10.1182/blood.V126.23.1571.1571

Published: 2015

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Alexandra Keller, MSc, Barbara Peter, DVM, Johannes Zuber, MD PhD, Philipp Bernhard Staber, MD PhD, Peter Bettelheim, MD, Peter Valent, MD, Emir Hadzijusufovic, DVM

Blood (2015) 126 (23): 2829.

https://doi.org/10.1182/blood.V126.23.2829.2829

Published: 2015

Journal Articles

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies

Geoffrey M. Matthews, Parinaz Mehdipour, Leonie A. Cluse, Katrina J. Falkenberg, Eric Wang, Mareike Roth, Fabio Santoro, Eva Vidacs, Kym Stanley, Colin M. House, James R. Rusche, Christopher R. Vakoc, Johannes Zuber, Saverio Minucci, Ricky W. Johnstone

Blood (2015) 126 (21): 2392–2403.

https://doi.org/10.1182/blood-2015-03-632984

Published: 2015

Includes: Supplemental data

NARROW

Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

SBNO2 is a critical mediator of STAT3-driven hematological malignancies

EVI1 drives leukemogenesis through aberrant ERG activation

Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

RNAi and CRISPR/Cas9 Based In Vivo Models for Drug Discovery

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Uncovering Key Downstream Effectors of PU.1 Tumor Suppression in Acute Myeloid Leukemia

The Transcription Factor PU.1 Controls a Reversible Differentiation Program in Acute Myeloid Leukemia

Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only